Apicularen A, a macrolide from Chondromyces sp., inhibits growth factor induced in vitro angiogenesis

Ho Jeong Kwon, Dong Hoon Kim, Joong Sub Shim, Jong Woong Ahn

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Apicularen A (Api A) was recently isolated from Chondromyces sp. as a potent antitumor agent. Because of its unique chemical structure, a macrolide with a highly unsaturated amide side chain, and potent growth inhibitory effect in various cancer cell lines, Api A is currently in clinical trial for cancer therapy. In the present study, the effect of Api A on in vitro angiogenesis of bovine aortic endothelial cells (BAECs) was investigated. Api A potently inhibited the proliferation of BAECs in a dose-dependent manner. Treatment of the endothelial cells with up to 10 ng/ml of the compound did not show any cytotoxicity. In addition, it inhibited basic fibroblast growth factor (bFGF)-induced invasion and capillary tube formation of BAECs at concentrations of 2-5 ng/ml. These results, therefore, demonstrate that Api A is a novel antiangiogenic agent and may suppress the growth of tumors, at least in part, by the inhibition of neovascularization.

Original languageEnglish
Pages (from-to)702-705
Number of pages4
JournalJournal of Microbiology and Biotechnology
Volume12
Issue number4
Publication statusPublished - 2002 Aug 1

Fingerprint

Macrolides
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Neoplasms
Angiogenesis Inhibitors
Fibroblast Growth Factor 2
Growth
Amides
Antineoplastic Agents
apicularen A
In Vitro Techniques
Clinical Trials
Cell Line

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

@article{0a9a642cba134c7b8fab28fc04b92707,
title = "Apicularen A, a macrolide from Chondromyces sp., inhibits growth factor induced in vitro angiogenesis",
abstract = "Apicularen A (Api A) was recently isolated from Chondromyces sp. as a potent antitumor agent. Because of its unique chemical structure, a macrolide with a highly unsaturated amide side chain, and potent growth inhibitory effect in various cancer cell lines, Api A is currently in clinical trial for cancer therapy. In the present study, the effect of Api A on in vitro angiogenesis of bovine aortic endothelial cells (BAECs) was investigated. Api A potently inhibited the proliferation of BAECs in a dose-dependent manner. Treatment of the endothelial cells with up to 10 ng/ml of the compound did not show any cytotoxicity. In addition, it inhibited basic fibroblast growth factor (bFGF)-induced invasion and capillary tube formation of BAECs at concentrations of 2-5 ng/ml. These results, therefore, demonstrate that Api A is a novel antiangiogenic agent and may suppress the growth of tumors, at least in part, by the inhibition of neovascularization.",
author = "Kwon, {Ho Jeong} and Kim, {Dong Hoon} and Shim, {Joong Sub} and Ahn, {Jong Woong}",
year = "2002",
month = "8",
day = "1",
language = "English",
volume = "12",
pages = "702--705",
journal = "Journal of Microbiology and Biotechnology",
issn = "1017-7825",
publisher = "Korean Society for Microbiolog and Biotechnology",
number = "4",

}

Apicularen A, a macrolide from Chondromyces sp., inhibits growth factor induced in vitro angiogenesis. / Kwon, Ho Jeong; Kim, Dong Hoon; Shim, Joong Sub; Ahn, Jong Woong.

In: Journal of Microbiology and Biotechnology, Vol. 12, No. 4, 01.08.2002, p. 702-705.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Apicularen A, a macrolide from Chondromyces sp., inhibits growth factor induced in vitro angiogenesis

AU - Kwon, Ho Jeong

AU - Kim, Dong Hoon

AU - Shim, Joong Sub

AU - Ahn, Jong Woong

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Apicularen A (Api A) was recently isolated from Chondromyces sp. as a potent antitumor agent. Because of its unique chemical structure, a macrolide with a highly unsaturated amide side chain, and potent growth inhibitory effect in various cancer cell lines, Api A is currently in clinical trial for cancer therapy. In the present study, the effect of Api A on in vitro angiogenesis of bovine aortic endothelial cells (BAECs) was investigated. Api A potently inhibited the proliferation of BAECs in a dose-dependent manner. Treatment of the endothelial cells with up to 10 ng/ml of the compound did not show any cytotoxicity. In addition, it inhibited basic fibroblast growth factor (bFGF)-induced invasion and capillary tube formation of BAECs at concentrations of 2-5 ng/ml. These results, therefore, demonstrate that Api A is a novel antiangiogenic agent and may suppress the growth of tumors, at least in part, by the inhibition of neovascularization.

AB - Apicularen A (Api A) was recently isolated from Chondromyces sp. as a potent antitumor agent. Because of its unique chemical structure, a macrolide with a highly unsaturated amide side chain, and potent growth inhibitory effect in various cancer cell lines, Api A is currently in clinical trial for cancer therapy. In the present study, the effect of Api A on in vitro angiogenesis of bovine aortic endothelial cells (BAECs) was investigated. Api A potently inhibited the proliferation of BAECs in a dose-dependent manner. Treatment of the endothelial cells with up to 10 ng/ml of the compound did not show any cytotoxicity. In addition, it inhibited basic fibroblast growth factor (bFGF)-induced invasion and capillary tube formation of BAECs at concentrations of 2-5 ng/ml. These results, therefore, demonstrate that Api A is a novel antiangiogenic agent and may suppress the growth of tumors, at least in part, by the inhibition of neovascularization.

UR - http://www.scopus.com/inward/record.url?scp=0036694418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036694418&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 702

EP - 705

JO - Journal of Microbiology and Biotechnology

JF - Journal of Microbiology and Biotechnology

SN - 1017-7825

IS - 4

ER -